2011
Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus
Shahabi S, Pellicciotta I, Hou J, Graceffa S, Huang GS, Samuelson RN, Goldberg GL. Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus. Rare Tumors 2011, 3: 41. PMID: 22355496, PMCID: PMC3282446, DOI: 10.4081/rt.2011.e41.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaNeuroendocrine tumorsUterine corpusGenital tractLarge cell neuro endocrine carcinomaLarge cell neuroendocrine tumorNeuro-endocrine carcinomaPrimary neuroendocrine tumorCell neuroendocrine carcinomaFemale genital tractPotential future therapeuticsEndocrine carcinomaAggressive treatmentInitial diagnosisUterine cervixNeuroendocrine carcinomaTreatment optionsRare caseClinical utilityChromogranin AOptimal managementTumorsFuture therapeuticsCervixCarcinoma
2002
Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma
Huang GS, Juretzka M, Ciaravino G, Kohler S, Teng NN. Liposomal Doxorubicin for Treatment of Metastatic Chemorefractory Vulvar Adenocarcinoma. Gynecologic Oncology 2002, 87: 313-318. PMID: 12468332, DOI: 10.1006/gyno.2002.6830.Peer-Reviewed Original ResearchConceptsVulvar adenocarcinomaLiposomal doxorubicinPelvic lymph node dissectionGroin lymph nodesLymph node dissectionExtramammary Paget's diseaseYears of survivalWarrants further investigationBulky involvementGroin irradiationInitial therapyNode dissectionMultiagent chemotherapyRadical vulvectomyGynecologic malignanciesMetastatic diseaseLymph nodesInitial diagnosisMetastatic lesionsPaget's diseaseDramatic regressionRare entityDoxil treatmentEffective treatmentSubcutaneous lesions